External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

MDS 2026

-
Coming soon
12:30 AM
Duration 60mins Seoul, Korea
NLRP3 inhibition in early-stage Parkinson’s disease: results of a Phase Ib study
Gennaro Pagano

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Seoul, Korea
Prasinezumab in early-stage Parkinson’s disease: additional data from the PADOVA study
Tania Nikolcheva

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Seoul, Korea
Modelling Parkinson’s disease progression to quantify long-term treatment effects via the conceptof ‘time saved’
Benjamin Ribba

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:00 AM
Duration 60mins Seoul, Korea
Neuromelanin-Sensitive MRI as a Marker of Clinical Severity and Disease Burden in Parkinson’s Disease
Rayo Akande

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:30 AM
Duration 60mins Seoul, Korea
Prasinezumab’s impact on neuromelanin- and iron-sensitive MRI biomarkers in Parkinson’s disease: findings from the PADOVA Phase IIb study
Thomas Kustermann, Rayo Akande

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:00 AM
Duration 60mins Seoul, Korea
Characterizing Longitudinal Motor Progression in Parkinson's Disease leveraging Digital Health Technologies in L-DOPA ON and OFF States
Michael Lindemann

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:30 AM
Duration 60mins Seoul, Korea
Robust location-agnostic turn speed estimation to ensure consistent remote monitoring of gait impairment in Parkinson’s disease
Michael Lindemann

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar